|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table 1: Characteristics of identified RCTs through the systematic review process** | | | | | | |
| **Characteristic, Demographic, or Comorbidity** | | **Period 1**  **N (%)** | **Period 2**  **N (%)** | **Period 3**  **N (%)** | **Period 4**  **N (%)** | **Cumulative**  **N (%)** |
| **Total Count of Trials 61 31 21 36 149**  **Trial Characteristics** | | | | | | |
| Hospitalized | | 47 (77%) | 17 (55%) | 13 (62%) | 25 (69%) | 102 (68%) |
| US | | 8 (13%) | 7 (23%) | 1 (5%) | 4 (11%) | 20 (13%) |
| **Trial Type** | |  |  |  |  |  |
| Treatment | | 50 (82%) | 18 (58%) | 17 (81%) | 28 (78%) | 113 (76%) |
| Vaccine | | 8 (13%) | 11 (35%) | 3 (14%) | 7 (19%) | 29 (19%) |
| Prophylaxis | | 3 (5%) | 1 (3%) | 1 (5%) | 0 | 5 (3%) |
| Anti-transmission | | 0 | 1 (3%) | 0 | 1 (3%) | 2 (1%) |
| **Reported Demographics** | | | | | | |
| Age | 61 (100%) | | 31 (100%) | 21 (100%) | 36 (100%) | 149 (100%) |
| Sex | | 59 (%) | 31 (100%) | 21 (100%) | 36 (100%) | 147 (99%) |
| Race | | 14 (%) | 18 (58%) | 6 (29%) | 12 (33%) | 40 (27%) |
| Body Mass Index (BMI) | | 26 (%) | 17 (55%) | 5 (24%) | 14 (39%) | 62 (42%) |
| **Reported Clinical Characteristics** | | | | | | |
| >=1 Comorbidity | | 48 (79%) | 25 (81%) | 18 (86%) | 19 (53%) | 110 (74%) |
| Smoke | | 17 (28%) | 13 (42%) | 5 (24%) | 8 (22%) | 43 (29%) |
| Oxygen Therapy | | 22 (36%) | 4 (13%) | 2 (10%) | 2 (6%) | 30 (20%) |
| Diabetes | | 42 (69%) | 23 (74%) | 14 (67%) | 18 (50%) | 97 (65%) |
| Hypertension | | 38 (62%) | 15 (48%) | 12 (57%) | 15 (42%) | 80 (54%) |
| General Heart Disease | | 26 (43%) | 20 (65%) | 10 (48%) | 7 (19%) | 63 (42%) |
| Asthma | | 14 (23%) | 6 (19%) | 7 (33%) | 4 (11%) | 31 (21%) |
| Kidney Disease | | 11 (18%) | 7 (23%) | 4 (19%) | 5 (6%) | 27 (18%) |
| Chronic Obstructive Pulmonary Disease (COPD) | | 11 (18%) | 6 (19%) | 6 (29%) | 3 (8%) | 26 (17%) |
| General Respiratory Disease | | 9 (15%) | 11 (35%) | 3 (14%) | 3 (8%) | 26 (17%) |
| Malignancy/Cancer | | 14 (23%) | 6 (19%) | 3 (14%) | 2 (6%) | 25 (17%) |
| Obesity | | 6 (10%) | 9 (29%) | 3 (14%) | 2 (6%) | 20 (13%) |
| Liver Disease | | 9 (15%) | 1 (3%) | 6 (29%) | 3 (8%) | 19 (13%) |
| Immunocompromised | | 9 (15%) | 0 | 2 (10%) | 3 (8%) | 14 (9%) |
| Hyperlipidemia | | 5 (8%) | 2 (6%) | 3 (14%) | 3 (8%) | 13 (9%) |
| Cerebrovascular Disease | | 7 (11%) | 0 | 3 (14%) | 1 (3%) | 11 (7%) |
| Heart Failure | | 2 (3%) | 3 (10%) | 4 (19%) | 0 | 9 (6%) |
| Thyroid Disease | | 3 (5%) | 1 (3%) | 4 (19%) | 0 | 8 (5%) |
| Tuberculosis | | 5 (8%) | 0 | 2 (10%) | 1 (3%) | 8 (5%) |
| HIV/AIDS | | 3 (5%) | 1 (3%) | 1 (5%) | 3 (8%) | 8 (5%) |
| Rheumatic Diseases | | 3 (5%) | 0 | 1 (5%) | 1 (3%) | 5 (3%) |
| COPD or Asthma | | 2 (3%) | 0 | 1 (5%) | 2 (6%) | 5 (3%) |
| Alcohol Use Disorder | | 2 (3%) | 0 | 0 | 0 | 2 (1%) |